Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: FVIII concentrate Clear all

Conditions: Hemophilia
Interventions: rFVIII; Drug
Lead sponsor: Craig Seaman; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hemophilia A With Inhibitors
Interventions: activated prothrombin complex concentrate (FEIBA); Drug
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 24 Months and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hemophilia A
Interventions: Nuwiq, Octanate, Wilate, Emicizumab, Recombinant factor VIIa (rFVIIa), Activated prothrombin complex concentrate (aPCC); Biological
Lead sponsor: Emory University; Other
Eligibility: Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hemophilia
Interventions: Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 8
States / cities: Orange, California • Minneapolis, Minnesota • Hackensack, New Jersey + 5 more

Conditions: Hemophilia A
Interventions: assessment of joint health and bone density; Other
Lead sponsor: Washington Institute for Coagulation; Other
Eligibility: 16 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • San Diego, California • San Antonio, Texas + 1 more

Conditions: Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Interventions: HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US); Drug
Lead sponsor: Hemab ApS; Industry
Eligibility: 16 Years to 69 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Hemophilia A, Immune Tolerance
Interventions: FVIII, Emicizumab; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 0 Years to 12 Years · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Von Willebrand Disease
Interventions: von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant); Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Loveland, Colorado • Gainesville, Florida • Jacksonville, Florida + 5 more

Conditions: Prevent Bleeding in Major Surgery
Interventions: human VWF/FVIII concentrate; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 6 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Indianapolis, Indiana • Chapel Hill, North Carolina • Milwaukee, Wisconsin

Conditions: Hemophilia A
Interventions: FVIII concentrate; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 13
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Lexington, Kentucky + 9 more

Conditions: Hemophilia A
Interventions: Emicizumab, FEIBA, rFVIIa; Drug
Lead sponsor: Emory University; Other
Eligibility: 6 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Von Willebrand Disease, Type 3
Interventions: Von Willebrand Factor Concentrates, Von Willebrand Factor Concentrates and Factor VIII Concentrates, Factor VIII Concentrates, Recombinant Activated Factor VII, Activated Prothrombin Complex Concentrate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Sacramento, California • Minneapolis, Minnesota • St Louis, Missouri

Conditions: Hemophilia A
Interventions: Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC), Emicizumab; Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Los Angeles, California • Flowood, Mississippi

Conditions: Hemophilia
Interventions: Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC); Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year to 11 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 8
States / cities: Los Angeles, California • Orange, California • Torrance, California + 4 more

Conditions: Von Willebrand Disease
Interventions: Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII), Marketed plasma-derived VWF/FVIII concentrate; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 10
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 7 more

Conditions: Hemophilia A
Interventions: Human-cl rhFVIII, Kogenate FS; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: Los Angeles, California • Sacramento, California • Denver, Colorado + 3 more

Conditions: Hemophilia A, Hemophilia B
Interventions: rFVIIIFc, rFIXFc, non-Fc FVIII replacement products, non-Fc FIX replacement products; Biological · Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 2
States / cities: Los Angeles, California • East Lansing, Michigan

Conditions: Von Willebrand Disease
Interventions: Wilate; Drug
Lead sponsor: Octapharma; Industry
Eligibility: Up to 5 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Search by objective public record fields.

Weight-based Dosing in Hemophilia A

Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors

Treatment of Hemophilia A Patients With FVIII Inhibitors

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

Preventing Inhibitor Recurrence Indefinitely

rVWF IN PROPHYLAXIS

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery

Hemophilia Inhibitor Previously Untreated Patient Study

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age